July 7–10, 2022 | Athens, Ga.
O-GlcNAc
regulation of cellular physiology and pathophysiology
O-GlcNAc regulation of cellular physiology and pathophysiology
July 7–10, 2022 | University of Georgia, Athens, Ga.
This conference will address the multitude of roles that the O-GlcNAc protein modification has in regulating nuclear and cytosolic proteins. It will bring together researchers from diverse fields to share their research, tools and experience in O-GlcNAc biology.
O-GlcNAc continues to be an underappreciated post-translational modification. However, the combination of advancements in determining protein-specific function and discovery that the modification is linked to many diseases have led to its recognition as an emerging target for understanding both normal and pathological processes in the cell.
The meeting will draw experts in O-GlcNAc biology from around the world to discuss how O-GlcNAc and O-GlcNAc cycling enzymes modulate protein function in basic biological processes as well as in disease states, including diabetes, cancer, cardiovascular disease and neurological diseases.
Graduate students and postdoctoral fellows, established in or wishing to learn about the field, are encouraged to attend and submit abstracts. The organizers will select oral presenters, and there will be a poster session.
Organizers
Image: Y835 H-bonds to a helix proximal to UDP-GlcNAc in OGT-substrate complex. Structure from Schimpl et al, 2012. PDB: 4AY6.
Sponsors
Program schedule
Thursday July 7
Friday July 8
Saturday July 9
Sunday July 10
Thursday agenda
Welcome and logistics
Lance Wells and Jerry Hart, University of Georgia
The cycling enzymes
Catalogue and meta-analysis of the O-GlcNAcome
Stephanie Olivier-Van Stichelen, Medical College of Wisconsin
Using cryo-EM to illuminate the domain arrangement and dimerization of O-GlcNAc transferase
Richard Meek, University of York
O-GlcNAc regulates the form and function of the neurofilament cytoskeleton
Michael Boyce, Duke University
Writing and erasing O-GlcNAc from target proteins in the cell
Christina Woo, Harvard University
Comprehensive characterization of post-translational modifications on O-GlcNAc cycling enzymes
Junfeng Ma, Georgetown University
Welcome reception and posters
Friday agenda
Coffee and continental breakfast
O-GlcNAcylation and the flow of genetic information
Coffee break at 10 a.m.
A complex interplay of RNA Pol II pausing, 5’ termination and elongation mediated by O-GlcNAcylation
Brian Lewis, National Cancer Institute
O-GlcNAc in epigenetics and signaling
John Hanover, National Institute of Diabetes and Digestive and Kidney Diseases
O-GlcNAcylation, a deceptive structural simplicity: the tree that hides the forest
Tony Lefebvre, University of Lille
Targeting the O-GlcNAc transferase to specific proteins using RNA aptamers
Yi Zhu, University of Georgia
Daily protein O-GlcNAcylation rhythm integrates circadian and metabolic signals to regulate time-of-day physiology
Xianhui Liu, University of California, Davis
Close cousins of O-GlcNAc-transferases: the O-fucosyl-transferases
Chris West, University of Georgia
Spatiotemporal control of subcellular O-GlcNAc signaling using light-inducible Opto-OGT
Qunxiang Ong, Institute of Molecular and Chemical Biology, A*STAR
Lunch and posters
O-GlcNAcylation and regulation of metabolism
Coffee break and posters at 4 p.m.
The intersection between O-GlcNAc, autophagy and cytoprotection
Natasha Zachara, Johns Hopkins University
The role of protein O-GlcNAcylation in mediating cardiomyocyte stress responses
John Chatham, University of Alabama at Birmingham
When pigs fly! O-GlcNAc in heart failure – From bench to bedside in 2022
Priya Umapatha, Johns Hopkins Medical Institute
IGF-1 reduces protein O-GlcNAcylation via AMPK activation in H9C2 cardiomyoblast cultured in high glucose media
Genaro Ramirez Correa , University of Texas Rio Grande Valley
Role of smooth muscle cell-derived O-GlcNAc transferase in diabetic atherosclerosis
Saugat Khanal, Northeast Ohio Medical University
GRASP55 senses energy and nutrient deprivation through O-GlcNAcylation to promote autophagosome–lysosome fusion and facilitate unconventional secretion of mutant huntingtin
Yanzhuang Wang, University of Michigan
Genetic deletion of MIOX ameliorates obesity-associated tubulo-interstitial injury via modulating O-GlcNAcylation of SREBP-1
Isha Sharma, Northwestern University
Dynamic regulation of cardiac myocyte voltage-gated calcium channels and calcium handling by O-GlcNAcylation
Andrew Ednie, Wright State University
Real-time chemical tools to capture and control sugar signaling in cells
Charlie Fehl, Wayne State University
Reception and posters
Saturday agenda
Coffee and continental breakfast
O-GlcNAcylation, immunity and signaling
Coffee break at 10 a.m.
O-GlcNAc and immunity: Chemical immunology as a powerful combination to investigate the roles of O-GlcNAcylation in the immune system
Alberto Fernandez–Tejada, CIC bioGUNE
Dual regulation of transcription in T lymphocytes by NF-kappaB c-Rel O-GlcNAcylation
Parameswaran Ramakrishnan, Case Western Reserve University
OGT in T cells and autoimmunity
Gabriela Gorelik, University of South Alabama
Intestinal epithelial STAT6 O-GlcNAcylation drives a concerted anti-helminth alarmin response
Hai-Bin Ruan, University of Minnesota
O-GlcNAcylation is a crucial post-translational modification for T helper 2 cell polarization by dendritic cells
Marjolein Quik, Leiden University Medical Center
O-GlcNAc signalling in natural and accelerated vascular aging
Paula R. Barros, Medical School of Ribeirao Preto
Protein O-GlcNAcylation affects paracrine regulation of fibroblast activation and turnover by keratinocytes
Yan Wang, Cleveland Clinic Lerner Research Institute
O-GlcNAc transferase regulates formation of clathrin-mediated coated pits
Sadia Rahmani, Toronto Metropolitan University
Lunch and posters
O-GlcNAcylation, cell growth and cancer
Coffee break and posters at 4 p.m.
O-GlcNAcylation: Linking signaling and metabolism in cancer and beyond
Maurico Reginato, Drexel University
Cell cycle and growth — Understanding the role of O-GlcNAcylation at cis-regulatory elements
Chad Slawson, University of Kansas Medical School
Importance of O-GlcNAcylation in glioblastoma tumorigenesis
Wagner B. Dias, Federal University of Rio de Janeiro
Regulation of the hedgehog pathway and medulloblastoma growth by glucose-induced O-GlcNAcylation
Huadong Pei, Georgetown University
Substrate dysregulation reveals a new role of O-GlcNAcase in p53 regulation
Chia-Wei Hu, University of Wisconsin–Madison
Defining the impact of Ca2+-dependent O-GlcNAcylation in melanoma progression
Jonathan Soboloff, Lewis Katz School of Medicine at Temple University
Regulation of O-linked N-acetyl glucosamine transferase (OGT) through E6 stimulation of the ubiquitin ligase activity of E6AP
Jun Yin, Georgia State University
Hedgehog activity regulates an O-GlcNAc-circuitry in mammary tumor-associated macrophages
Lalita Shevde–Samant, University of Alabama at Birmingham
New proteomic and chemical genetic tools to study OGT and O-GlcNAc signaling
Samuel A. Myers, La Jolla Institute for Immunology
Proteomic quantification of site-specific interplay between O-GlcNAcylation and phosphorylation in diabetic hearts
Amit Das, University of Texas Rio Grande Valley
Reception and posters
Sunday agenda
Coffee and continental breakfast
O-GlcNAcylation and neuronal functions and disease
Coffee break and posters at 10 a.m.
O-GlcNAc cycling regulates food intake by mediating meal memories
Olof Lagerlöf, Umeå University
Chemical biology approaches for investigating the O-GlcNAc modification
David Vocadlo, Simon Fraser University
Build it to understand it: synthesis of O-GlcNAc modified proteins
Matthew Pratt, University of Southern California
Utilizing causal X-linked intellectual disability variants to gain insight into the O-GlcNAc transferase enzyme
Johnathan Mayfield, University of Georgia
Missense mutations in OGT associated with Intellectual Disability cause O-GlcNAcylation homeostasis alteration and cognitive defects in mice
Florence Authier, University of Dundee
Human pharmacology highlights the potential of the OGA Iinhibitor ASN51 as an ideal once-a-day oral drug for the treatment of neurodegenerative diseases
Ryan Schubert, Asceneuron SA
Concluding remarks
Lance Wells and Jerry Hart, University of Georgia